Summer Sale

50% off Premium Yearly

00days
00hrs
00mins
00secs

Rocket Doctor AI (AIDR-CSE)

Investor Insights
star iconJun 11, 2026, 12:00 am

This summary was created by AI, based on 4 opinions in the last 12 months.

Rocket Doctor AI, trading under the symbol AIDR-CSE, presents an innovative approach to healthcare with its AI-driven platform, likened to a 'Shopify' for doctors. The platform's model allows practitioners to maintain continuity with their patients while providing access to a comprehensive medical library developed over eight years. Currently operational in Canada and expanding into major U.S. markets, the company is gaining traction with partnerships, including several prominent insurance providers. However, it faces challenges as it operates at a loss with minimal revenue and no current analyst coverage. Despite the promising technology and strategic support from insurers, expert opinions suggest it remains early to determine its market potential without substantial sales data.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
MDMO
HOLD

Doctors can use a "Shopify" model to market their "business" and get repeat patients, while accessing a global medical library that's been created with AI. Rolled out in Canada, now in some big US states, and being covered by US insurance. Expects it to be EBITDA-positive by year's end.

BUY

Sort of a "Shopify" model for doctors. Lets a doctor see the same patients, compared to a Teladoc model when you never know who you're going to get. Allows doctors to specialize. Built-in medical library helps with diagnoses. Now ramping up from Canada to US, revenues should increase, and eventually will be EBITDA-positive.

RISKY
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

AIDR is quite small at $75M market cap, after a 57% gain this year. It provides healthcare software solutions. Essentially, an AI doctor. But, currently it has minimal revenue, losses and negative cash flow. No analyst coverage. It does have some partnerships with insurance companies, with large numbers of members, so there is some potential here. But we need to see some sales in order to gauge what future profitability might be. There is competition in the space, certainly, as well. Insiders own 3%. While interesting, we would consider it too early here.
Unlock Premium - Try 5i Free  

BUY

Uses AI with its global library of medicine that it custom-built over 8 years. Different from using ChatGPT, which looks everywhere trying to find an answer. They've run the program through the 12 patient scenarios given to med students, and it scored well enough to pass the exam. 

Doctors like it because it helps with triage. Insurance companies like it because it cuts down costs. Has proven itself in Canada, and now going after the bigger market in the US -- starting to add the who's who of insurers such as UNH, Medicare, Medicaid, and HUM.

He wanted to use it as a Top Pick today, but it's just a bit too small of a market cap.

Showing 1 to 4 of 4 entries
  • «
  • 1
  • »

Rocket Doctor AI (AIDR-CSE) Frequently Asked Questions

What is Rocket Doctor AI stock symbol?

Rocket Doctor AI is a OTC stock, trading under the symbol AIDR-CSE on the undefined (undefined). It is usually referred to as or AIDR-CSE

Is Rocket Doctor AI a buy or a sell?

In the last year, 4 stock analysts issued a Buy, Sell, or Hold rating on AIDR-CSE. 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is BUY. Read the latest stock experts' ratings for Rocket Doctor AI.

Is Rocket Doctor AI a good investment or a top pick?

Rocket Doctor AI was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Rocket Doctor AI.

Why is Rocket Doctor AI stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Rocket Doctor AI.

Is Rocket Doctor AI worth watching?

Rocket Doctor AI is followed by 9 investors on Stockchase and is a trending stock that is worth watching.

Star iconStar iconStar iconStar iconStar half icon
4.5(4)
Based on 4 expert opinions: 3 buy 1 hold 0 sell